August 8, 2007 – A new report from IMV Limited suggests controversy among urologists and radiation oncologists regarding optimal treatments for patients with localized prostate cancer.

August 8, 2007 - Masimo Corp. announced the pricing of its initial public offering of 11,916,626 shares of common stock at a price of $17 per share.

Masimo intends to use the net proceeds from the offering for capital expenditures and the placement of equipment, sales and marketing activities to support the ongoing commercialization of the Masimo SET and Masimo Rainbow SET pulse oximetry products, sales force expansion, research and development activities and including support of hardware and software product development and clinical study initiatives.

August 8, 2007 – Accuray Inc. announced that use of its CyberKnife Robotic Radiosurgery System to noninvasively treat extracranial tumors has increased 75 percent in 2007.

The number of lung cancer patients treated with the system doubled, while the number of prostate cancer procedures with the system quadrupled over the past year.

Radiosurgery has historically been used exclusively for the treatment of brain tumors. The CyberKnife System, however, is FDA cleared to treat tumors anywhere in the body, including the spine, lungs, prostate, liver and pancreas.

August 8, 2007 – Emageon Inc. reported financial results for its second quarter ended June 30, 2007, reflecting net positive operating cash flow of $3.7 million for the second quarter of 2007, an improvement of $7.7 million over net negative operating cash flow of $4.0 million in first quarter 2007. For the six months ended June 30, 2007, net cash used in operations was $0.3 million. At June 30, 2007, cash and marketable securities totaled $20.9 million, compared to $23.0 million at December 31, 2006.

August 7, 2007 - BSD Medical Corp. announced that the Centers for Medicare and Medicaid Services (CMS) has proposed an approximate 86 percent increase in the reimbursement rate for all of the CMS codes applicable to the use of BSD cancer treatment systems for hospital outpatient procedures.

The new proposed reimbursement rates will be finalized in November and become effective Jan. 1, 2008. Increases ranging from 14 to 44 percent have also been proposed for freestanding clinics.